TRVI analyst estimates
Trevi Therapeutics (TRVI) analyst ratings, the average price target and its range, and every firm's latest call.
TRVI analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 7, 2026 | Raymond James | Trevi Therapeutics (TRVI) PT Raised to $40 at Raymond James | $40.00 |
| Aug 7, 2026 | Oppenheimer | Trevi Therapeutics price target raised to $25 from $24 at Oppenheimer | $25.00 |
| Aug 7, 2026 | Morgan Stanley | Trevi Therapeutics price target raised to $23 from $20 at Morgan Stanley | $23.00 |
| Jul 20, 2026 | H.C. Wainwright | Trevi Therapeutics (TRVI) PT Raised to $24 at H.C. Wainwright | $24.00 |
| Jul 20, 2026 | BMO Capital | Trevi Therapeutics initiated with an Outperform at BMO Capital | $36.00 |
| May 8, 2026 | Stifel Nicolaus | Trevi Therapeutics price target raised to $30 from $18 at Stifel | $30.00 |
| May 6, 2026 | Morgan Stanley | Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley | $20.00 |
| Dec 19, 2025 | Stifel Nicolaus | Trevi Therapeutics price target raised to $18 from $15 at Stifel | $18.00 |
| Nov 19, 2025 | Leerink Partners | Trevi Therapeutics (TRVI) PT Raised to $16 at Leerink Partners | $16.00 |
| Nov 14, 2025 | Oppenheimer | Trevi Therapeutics (TRVI) PT Raised to $24 at Oppenheimer | $24.00 |
| Nov 14, 2025 | Morgan Stanley | Trevi Therapeutics price target raised to $19 from $18 at Morgan Stanley | $19.00 |
| Oct 22, 2024 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Trevi Therapeutics (TRVI) | $6.00 |
| Oct 4, 2024 | B.Riley Financial | B.Riley Reiterates Buy Rating on Trevi Therapeutics (TRVI) | $6.00 |
| Jul 9, 2022 | Oppenheimer | Trevi Therapeutics (TRVI) Stock: $12 Target And Outperform Rating | $12.00 |
- 12 firms rate TRVI: 12 buy, 0 hold, 0 sell.
- The average price target is $29.67 from 6 analysts, from $23.00 to $40.00.
Updated 2026-11-03 00:01 UTC